Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Case 69% Improvement Relative Risk c19vitamind.com Hosseini et al. NCT04483635 PROTECT Vitamin D RCT Prophylaxis Favors vitamin D Favors control
Hosseini, 33 patient vitamin D prophylaxis RCT: 69% fewer cases [p=0.45] https://c19p.org/hosseini4
copied to clipboard
Prevention of COVID-19 with Oral Vitamin D Supplemental Therapy in Essential healthCare Teams (PROTECT): Ancillary Study of a Randomized Controlled Trial
Hosseini et al., NCT04483635 (Preprint)
20 May 2022    Source   PDF   Share   Tweet
Early terminated prophylaxis RCT for healthcare workers in Canada, showing 0/18 cases with vitamin D prophylaxis vs. 1/15 for control. Results are published in [Hosseini]. 100,000IU cholecalciferol at baseline, 10,000IU weekly for 16 weeks.
risk of case, 68.8% lower, RR 0.31, p = 0.45, treatment 0 of 18 (0.0%), control 1 of 15 (6.7%), NNT 15, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hosseini et al., 5/20/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Canada, North America, preprint, 1 author, dosage 100,000IU day 1, 10,000IU day 7, 10,000IU day 14, 10,000IU day 21, 10,000IU day 28, 100,000IU cholecalciferol at baseline, 10,000IU weekly for 16 weeks, trial NCT04483635 (PROTECT).
All Studies   Meta Analysis
This PaperVitamin DAll
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit